Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

Reck, Martin; Rodríguez‐Abreu, Delvys; Robinson, Andrew; Hui, Rina; Csőszi, Tibor; Fülöp, Andrea; Gottfried, Maya; Peled, Nir; Tafreshi, Ali; Cuffe, Sinéad; O’ Brien, Mary; Rao, Suman; Hotta, Katsuyuki; Vandormael, Kristel; Riccio, Antonio; Yang, Jing; Catherine Pietanza, M.; R. Brahmer, Julie

doi:10.1200/jco.18.00149

Public

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

Published in Journal of Clinical Oncology • Jan 8, 2019

Authors:

Martin Reck

Delvys Rodríguez‐Abreu

Andrew Robinson

Abstract

PURPOSE: In the randomized, open-label, phase III KEYNOTE-024 study, pembrolizumab significantly improved progression-free survival and overall survival (OS) compared with platinum-based chemotherapy in patients with previously untreated advanced non-small-cell lung cancer (NSCLC) with a programmed ...

Subject

Pembrolizumab

Medicine

Lung cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!